Company Directory / Alternative Medicine
Public · NASDAQ:PRAXFor profitAlternative MedicineCambridge, United States
Praxis Precision Medicines
Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
- Founded
- 2015 11 years ago
- Staff
- 51-100 band, as listed
- Followers
- - on LinkedIn
- Funding
- $575M as listed, currency not stated
Set against six million companies
Size
51-100 people: larger than 75% of companies with a size listed
Age
11 years old.
Reach
Website ranked #3,528,337 in the world for traffic, about 4k visits a month.
What it does
Alternative MedicineBiotechnologyHealth CareMedicalPrecision Medicine
Funding, as listed
$575M currency not stated
- Rounds6
- LatestPost ipo equity, Mar 2024
- Investors15, 1 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about Praxis Precision Medicines, field by field. Contact details are held but never shown.
The company
- Name
- Praxis Precision Medicines
- Type
- For profit
- Status
- Public · NASDAQ:PRAX
- Founded
- 2015
- Founders
- David Goldstein, Kiran Reddy, Steven Petrou
- Industry
- Alternative Medicine
- Categories
- Alternative Medicine, Biotechnology, Health Care, Medical, Precision Medicine
Where
- City
- Cambridge
- Country
- United States
- Markets
- Greater Boston Area, East Coast, New England, Northeastern US
Size and reach
- Staff band
- 51-100
- Web traffic rank
- #3,528,337
- Monthly web visits
- 3,670
Funding, as listed
- Total
- 575,000,000 (currency not stated)
- Rounds
- 6
- Latest round
- Post ipo equity
- Latest round date
- Mar 2024
- Investors
- 15
- Lead investors
- 1
- Stock listing
- NASDAQ:PRAX
- Listing status
- public
About this record
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Praxis Precision Medicines may be growing as evidenced by several indicators. The company has reported positive results from its PRAX-628 study, which is a sign of successful advancements in its product pipeline. Additionally, there has been a significant increase in short interest in the company's stock, growing by 77.1%, which often reflects heightened investor attention and speculative interest in a company's future prospects. Furthermore, Praxis Precision Medicines has announced a proposed public offering, which typically aims to raise capital for further growth and development activities. The company also received PRIME designation from the EMA for one of its treatments, indicating recognition of the treatment's potential benefit and the company's progress in the regulatory process.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
Alternative Medicine in United States.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 1,637,054 companies in United States and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.